Chest Email Content Delivery
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Guest Access | Sign In via User Name/Password
This Article
Right arrow Full Text (PDF) Free
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Article Archive
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Klotz, T. A.
Right arrow Articles by Zipser, R. D.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Klotz, T. A.
Right arrow Articles by Zipser, R. D.

Chest, Vol 85, 329-335, Copyright © 1984 by American College of Chest Physicians

ARTICLES

Urinary excretion of thromboxane B2 in patients with venous thromboembolic disease

TA Klotz, LS Cohn and RD Zipser

Platelet activation occurs in the initial phase of venous thrombus formation. To determine if thromboxanes (Tx) are released during this process and if Tx measurements are useful in the diagnosis, urinary immunoreactive TxB2 was measured by a rapid, inexpensive assay in 100 consecutive patients with suspected thromboembolic disease. Urinary iTxB2 was not increased in patients who took aspirin, nor in patients studied several weeks after onset of symptoms. Of the remaining patients, iTxB2 was increased in 11 of 15 with confirmed deep vein thrombosis and in seven of ten with confirmed pulmonary emboli. Of the 54 patients in whom acute thrombosis was excluded, iTxB2 was increased in only four (7 percent). A second study evaluated 25 additional patients with nondiagnostic lung scans who required pulmonary angiography; iTxB2 was increased in seven of ten with positive angiograms and in 0 of 15 with negative angiograms. The three patients with negative iTxB2 and positive angiograms were receiving heparin when studied. These data suggest that, in the absence of aspirin, platelet Tx is released during thrombus formation. In combination with other noninvasive tests, urinary iTxB2 is a useful adjunct to diagnosing acute thromboembolic disease.


This article has been cited by other articles:


Home page
 J. Pharmacol. Exp. Ther.Home page
A. Ghuysen, B. Lambermont, J.-M. Dogne, P. Kolh, V. Tchana-Sato, P. Morimont, D. Magis, J. Hanson, P. Segers, and V. D'Orio
Effect of BM-573 [N-Terbutyl-N'-[2-(4'-methylphenylamino)-5-nitro-benzenesulfonyl]urea], a Dual Thromboxane Synthase Inhibitor and Thromboxane Receptor Antagonist, in a Porcine Model of Acute Pulmonary Embolism
J. Pharmacol. Exp. Ther., September 1, 2004; 310(3): 964 - 972.
[Abstract] [Full Text] [PDF]

Home page
 CirculationHome page
P. Sobieszczyk, M. C. Fishbein, and S. Z. Goldhaber
Acute Pulmonary Embolism: Don't Ignore the Platelet
Circulation, October 1, 2002; 106(14): 1748 - 1749.
[Full Text] [PDF]

Home page
 Eur Heart JHome page
S. Kamath, A.D. Blann, and G.Y.H. Lip
Platelet activation: assessment and quantification
Eur. Heart J., September 1, 2001; 22(17): 1561 - 1571.
[PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 1984 by the American College of Chest Physicians.